Testosterone in women: useful, narrow, and oversold
One indication in women has good randomised evidence behind it, no product is approved for female use, and a man on topical gel can transfer testosterone to the people he touches.
This is a site about men, and this page exists for three reasons. Men ask, because a partner has been offered testosterone or has read that it will fix her energy, and the question arrives in a men's appointment. The arguments used to sell testosterone to women are the same ones used on men — that a symptom means a deficiency, that a number means a diagnosis, that more is better — applied to a thinner evidence base with no approved product. And a man using a topical gel can transfer testosterone to a partner or a child, which is a labelled warning rather than a theoretical concern. The clinical detail — dosing, monitoring, and how testosterone fits alongside estrogen and progesterone — sits on the sister site: testosterone therapy for women, at MenoExperts.
Women produce testosterone, at female concentrations
Testosterone in women comes from the ovaries and the adrenal glands and circulates at roughly a tenth to a twentieth of male concentrations. It is a functioning part of female endocrine physiology rather than a vestigial male hormone, and it is also the substrate from which some estradiol is made.
The trajectory is commonly misdescribed. Testosterone in women declines gradually across the reproductive years, beginning well before menopause, and does not fall away at menopause the way estradiol does. The background to the 2019 international consensus statement makes this point explicitly, and the consequence matters: menopause is not the event that explains a woman's testosterone level, so a low level is not automatically a menopausal finding. Surgical menopause is the exception. Removal of both ovaries produces an abrupt fall in circulating testosterone, which is a different clinical situation from natural menopause.
The one indication with randomised support
Hypoactive sexual desire disorder in postmenopausal women — persistently low sexual desire that causes the woman herself distress — is the only indication endorsed by the 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women, led by Susan Davis and published simultaneously in Climacteric, Maturitas, the Journal of Sexual Medicine and the Journal of Clinical Endocrinology and Metabolism. Its endorsements include the International Menopause Society, the Endocrine Society, the European Menopause and Andropause Society, the International Society for Sexual Medicine, ISSWSH, the North American Menopause Society and the Royal College of Obstetricians and Gynaecologists among others. The disagreement that characterises much of the testosterone field is largely absent here.
The evidence underneath it is a systematic review and meta-analysis by Rakibul Islam and colleagues in The Lancet Diabetes & Endocrinology in 2019: 36 randomised controlled trials, 8,480 women. In postmenopausal women, testosterone improved satisfactory sexual event frequency (mean difference 0.85, 95% CI 0.52–1.18), sexual desire (standardised mean difference 0.36, 95% CI 0.22–0.50), arousal, orgasm, pleasure, responsiveness and self-image, and reduced sexual distress (SMD −0.27, 95% CI −0.36 to −0.17).
The magnitude of that first figure is worth stating in ordinary terms. A mean difference of 0.85 satisfactory sexual events is roughly one additional event per month over placebo: a reproducible effect across a large number of trials, and a modest one. Some women find it clearly worth having and some do not, and a woman deciding is entitled to the figure rather than an adjective.
What it is not established for
Testosterone is marketed to women for energy, mood, brain fog, muscle, bone, weight and ageing. The same Lancet meta-analysis reported no effect of testosterone on body composition, musculoskeletal variables or cognitive measures, with the authors noting that relatively few women contributed data to those outcomes. That is weaker than a demonstration that it does not work: the trials that would justify prescribing for those reasons have not been done, and the ones that exist are null. Fatigue and low energy in a woman warrant the same workup they warrant in a man — thyroid, iron, sleep, depression, medication and the rest of the list — before a hormone is assumed to be the cause.
Route of administration matters for one measurable harm. Oral testosterone raised LDL cholesterol and lowered HDL and triglycerides; non-oral routes, transdermal patch or cream, did not. That is the reason transdermal delivery is recommended rather than a matter of preference.
No approved product, which shapes how it is prescribed
Every prescription of testosterone to a woman in the United States is off-label; no female formulation is approved, and the consensus documents state this themselves. The ISSWSH clinical practice guideline (Parish, Simon, Davis and colleagues, Journal of Sexual Medicine, 2021) sets out how to prescribe within that constraint: a government-approved male transdermal formulation, used cautiously at approximately a tenth of the male dose, with total testosterone monitored to keep concentrations within the premenopausal physiologic range rather than above it.
The same guideline states that compounded products cannot be recommended, on the grounds of absent efficacy and safety data. Pellets carry a specific problem: once implanted the dose cannot be adjusted, and levels are frequently supraphysiologic for months, so a woman who develops androgenic side effects has no way to stop the exposure.
A level does not make the diagnosis
The ISSWSH guideline states that a total testosterone level should not be used to diagnose hypoactive sexual desire disorder. It is measured as a baseline, so that treatment can be monitored and supraphysiologic exposure avoided, not to establish that a problem exists. That is the same principle this site applies in men, reached independently by a different set of societies looking at a different sex: the symptom and its context make the diagnosis, and the laboratory value indicates what to do next and whether the target has been overshot.
Safety, and where the data stop
In the randomised trials, testosterone made acne and unwanted hair growth significantly more likely and produced a small overall increase in weight. No serious adverse events were recorded. Voice deepening and clitoral enlargement, the side effects women most often ask about, are associated with supraphysiologic exposure rather than physiologic dosing, which is why levels are monitored.
Long-term safety has not been established. Breast cancer outcomes and cardiovascular outcomes over years of use have not been studied in trials designed to answer those questions, so a claim that testosterone is proven safe over a decade describes evidence that does not exist in either direction.
Transfer from topical gel
Topical testosterone gels carry a boxed warning for secondary exposure. Virilization has been reported in children who came into contact with treated skin, and the FDA required the warning after those reports; women can be exposed by the same route. The labelled precautions are specific — apply only to the sites the product's label specifies, cover the area with clothing once dry, wash hands with soap and water immediately afterwards, and wash the application site before skin-to-skin contact with anyone. New acne, unusual hair growth or menstrual changes in a partner of a man using gel belong near the top of the differential rather than the bottom.
Injectable and pellet formulations do not carry this risk. Where transfer cannot be managed reliably in a household, that is a legitimate reason to discuss a change of formulation, and which formulation suits a particular household is part of the individual assessment at the practice — see treatment.
Questions patients ask
My wife's testosterone is low, so she needs treatment.
A low level in a woman is not by itself a reason to treat.
What the evidence showsThe ISSWSH clinical practice guideline states that a total testosterone level should not be used to diagnose hypoactive sexual desire disorder; it is measured as a baseline for monitoring. The indication is defined by distressing low desire.
What remains uncertainNothing about the recommendation; the societies are unusually aligned here.
Bottom lineAs in men, the diagnosis is clinical and the number guides the dose.
Strong
Testosterone will fix my partner's fatigue.
No trial evidence supports that use.
What the evidence showsThe 2019 Lancet meta-analysis of 36 trials found no effect of testosterone on body composition, musculoskeletal variables or cognitive measures, though relatively few women contributed data to those outcomes. Energy is not an indication in any society statement.
What remains uncertainWhether adequately powered trials of wellbeing outcomes would show anything. They have not been done.
Bottom lineFatigue needs a workup rather than a hormone.
Limited
Testosterone therapy for women is FDA-approved.
No. Every such prescription in the United States is off-label.
What the evidence showsNo testosterone product is approved for women in the US. The ISSWSH guideline describes using an approved male transdermal formulation cautiously at roughly a tenth of the male dose, with monitoring to keep levels in the premenopausal physiologic range.
What remains uncertainWhether a female-specific product will be approved; one is licensed in Australia.
Bottom lineOff-label is not the same as unreasonable, and it should be disclosed and consented.
Strong
Pellets are the convenient option.
The convenience is the problem.
What the evidence showsThe ISSWSH guideline does not recommend compounded products, citing absent efficacy and safety data. Pellets deliver a dose that cannot be adjusted after implantation and frequently produce supraphysiologic levels for months.
What remains uncertainNothing that would change the recommendation.
Bottom lineTransdermal, monitored and adjustable.
Limited
Testosterone is proven safe for women long-term.
It is neither proven safe nor proven unsafe; the studies do not exist.
What the evidence showsRandomised trials recorded no serious adverse events, with acne and hair growth significantly more common. Long-term breast and cardiovascular outcomes have not been established, as both the global consensus statement and the ISSWSH guideline state directly.
What remains uncertainLong-term safety, which is the central open question.
Bottom lineShort-term physiologic dosing appears safe. Beyond that the evidence runs out.
Mixed — Strong short-term, Limited long-term
My testosterone gel cannot affect anyone else.
It can, and the label says so.
What the evidence showsTopical testosterone gels carry a boxed warning for secondary exposure, added after reports of virilization in children who contacted treated skin. Women can be exposed by the same route.
What remains uncertainHow often this happens in practice with correct application.
Bottom lineCover the site, wash hands, wash the site before contact.
Strong
Ready for testosterone care built on a diagnosis?
The first step is a full endocrine evaluation, not a prescription. We see patients across San Diego County and welcome referrals from other physicians.
Our endocrinologists evaluate low testosterone in La Jolla, La Mesa and Poway: low testosterone care at Diabetes & Endocrine Specialists.


